GARAOTUS提供MedGenome基因組分析整體解決方案,並提升其89%基因分析效能
發佈日期:2022-07-30
攤位號碼:尚未更新
Joint Genomic Analytics Platform from Advantech, GARAOTUS and WASAI Delivers Significant Workflow and Execution Pipeline Improvements.
The solution combines Advantech SKY-8232D servers powered by 3rd generation Intel Xeon Scalable processors with WASAI acceleration on Intel FPGA cards to significantly cut genomics workload processing time while improving TCO. MedGenome Inc., a global leader in personalized medicine, is utilizing the joint solution for rare disease and Parkinson’s disease research in India.
Advances in the use of genomics to better understand rare diseases have come as increasingly powerful compute technology has allowed researchers to work with larger pieces of the human genome to the point now where massive genomic file data sets, totaling over 300 GB, are required now that all 3 billion DNA base pairs have been sequenced and mapped. These large data sets can require more than 40 hours to process even using the most advanced computing resources with requirements growing exponentially to meet new applications and increased demand.
The IT departments supporting these researchers and doctors need every possible advance in performance from both hardware and software. Reducing total cost of ownership (TCO) for such solutions is an important goal to sequence the genome and make genomics a part of a wider range of treatment plans - scaling to the delivery of personalized medicine.
To help enable this, Advantech has partnered with industry leaders GARAOTUS and WASAI to develop a new genomic analytics platform based on its SKY-8232D, SKY-9232D and SKY-5240 Intel Select Solutions for Genomics Analytics v2 verified servers. The solution combines 3rd Gen Intel Xeon Scalable processors and field programmable gate arrays (FPGAs) cards from Intel and leverages WASAI acceleration for genomic secondary analysis, which targets the BWA-MEM and GATK HaplotypeCaller algorithms. With this novel approach, an Intel FPGA card can process billions of DNA base pairs in parallel providing cost efficient, accurate and fast genome processing to address the challenges of secondary analysis for genome sequencing.
更多參展商新聞稿
- 瑞士Levitronix第三方研究報告:比較不同泵系統對蛋白質施加的機械剪切應力的研究 瑞士商力威磁浮技術有限公司 台灣分公司 / 2022-08-01
- 瑞士Levitronix第三方研究報告:比較不同泵系統對CHO細胞施加的機械剪切應力的研究 瑞士商力威磁浮技術有限公司 台灣分公司 / 2022-08-01
- 瑞士Levitronix第三方研究報告:不同泵系統的顆粒物脫落程度比較與評估 瑞士商力威磁浮技術有限公司 台灣分公司 / 2022-08-01
- 2022亞洲生技大展盛大開幕,微體生醫展出最新亮眼成績 微體生物醫學股份有限公司 / 2022-07-30
- FDA批准國鼎生技申請新冠肺炎新藥之 Pre-EUA Meeting Request會議請求 國鼎生物科技股份有限公司 / 2022-07-30
- Antroquinonol (HOCENA), 致力研發創新, 突破,增進生活品質理想藥物 國鼎生物科技股份有限公司 / 2022-07-30
- 產研攜手共創AI生醫加速器-國衛院與華碩集團合作簽約儀式 財團法人國家衛生研究院 / 2022-07-29
- 義大利攜7大廠商第三度參展BIO ASIA亞洲生技大會 義大利經濟貿易文化推廣辦事處貿易組 / 2022-07-29
- 蔡英文:2021國內生技營業額破七千億台幣! 盼展會加持串接價值鏈 環球生技多媒體股份有限公司 / 2022-07-28
- 串接亞洲生技價值鏈 2022亞洲生技大會盛大回歸! 環球生技多媒體股份有限公司 / 2022-07-28
- 研生生醫參加北美生技展示獨特生物技術研發抗體開發平台及新藥開發進展 研生生醫股份有限公司 / 2022-07-28
- 研生生醫開發出對抗COVID-19 Omicron 變異株的高度中和效力治療性抗體 研生生醫股份有限公司 / 2022-07-28
- 新冠有解?研生發現抗病毒變異株人類抗體 研生生醫股份有限公司 / 2022-07-28
- IPO也要話題行銷 台灣健康產業協會 / 2022-07-28
- 艾明康生技公司開發居家視力檢測「艾明康守護孩子視力方案」,別讓「假性近視」變成真近視 艾明康生技股份有限公司 / 2022-07-28
- 2022 亞洲生技大展, 中山醫學大學專家與您有約 中山醫學大學 / 2022-07-27
- 2022「台北生技獎」揭曉 倍利科技獲「跨域卓越獎」殊榮 倍利科技股份有限公司 / 2022-07-27
- 逸達生技 前列腺癌新劑型新藥 CAMCEVI 42毫克正式於美國上市 逸達生物科技股份有限公司 / 2022-07-27
- 逸達前列腺癌新劑型新藥 CAMCEVI 通過歐盟EMA新藥上市許可 逸達生物科技股份有限公司 / 2022-07-27
- 霖揚深化胜肽與重組蛋白藥物CDMO服務 霖揚生技製藥股份有限公司 / 2022-07-27